Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonidegib and Pembrolizumab in Advanced Solid Tumors
NCT04007744Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Feb 2020
- Primary completion
- May 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonidegib in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 4 more, sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 21 days and Objective Response Rate. Started Feb 2020; status: active, not recruiting.
02
Drugs
sonidegib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)melanomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04007744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007744.